Two former Trump administration officials have taken to the Wall Street Journal to defend the practices of pharmacy benefit managers, the middlemen who negotiate drug prices with the manufacturers on behalf of the insurers. The authors are perplexed as to why fellow Republicans would be concerned about these middlemen using their leverage to extract “rebates” from drug manufacturers. They claim the rebates result in lower premiums and savings for patients.
top of page
bottom of page
Comments